Search

Author/Creator Siegmund, B.

1. Co‐morbidities and bleeding in elderly patients with haemophilia—A survey of the German, Austrian and Swiss Society of Thrombosis and Haemostasis Research (GTH). Issue 5 (21st June 2017)

Authors:
Miesbach, W.; Reitter‐Pfoertner, S.‐E.; Klamroth, R.; Langer, F.; Wolf, H.‐H.; Tiede, A.; Siegmund, B.; Scholz, U.; Müller, P. R.; Eichler, H.; Pabinger, I.
Journal:
Haemophilia
Issue:
Volume 23:Issue 5(2017)
Page Start:
721
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. FRI0323 THE PRESENCE OF SPONDYLOARTHRITIS IS ASSOCIATED WITH HIGHER CLINICAL DISEASE ACTIVITY IN PATIENTS WITH EARLY CROHN'S DISEASE: RESULTS OF A PROSPECTIVE COHORT STUDY. (2nd June 2020)

Authors:
Rios Rodriguez, V.; Protopopov, M.; Proft, F.; Lüders, S.; Rademacher, J.; Haibel, H.; Verba, M.; Sieper, J.; Sonnenberg, E.; Schumann, M.; Kredel, L. I.; Siegmund, B.; Poddubnyy, D.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79(2020)Supplement 1
Page Start:
753
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. High prevalence and functional effects of serum antineuronal antibodies in patients with gastrointestinal disorders. Issue 6 (18th January 2018)

Authors:
Lütt, A.; Michel, K.; Krüger, D.; Volz, M. S.; Nassir, M.; Schulz, E.; Poralla, L.; Tangermann, P.; Bojarski, C.; Höltje, M.; Teegen, B.; Stöcker, W.; Schemann, M.; Siegmund, B.; Prüss, H.
Journal:
Neurogastroenterology & motility
Issue:
Volume 30:Issue 6(2018)
Page Start:
n/a
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Inhibitor development and mortality in non‐severe hemophilia A. (10th June 2015)

Authors:
Eckhardt, C. L.; Loomans, J. I.; van Velzen, A. S.; Peters, M.; Mauser‐Bunschoten, E. P.; Schwaab, R.; Mazzucconi, M. G.; Tagliaferri, A.; Siegmund, B.; Reitter‐Pfoertner, S. E.; van der Bom, J. G.; Fijnvandraat, K.; the INSIGHT Study Group; Fijnvandraat, K.; Peters, M.; Kamphuisen, P. W.; Kamphu...
Journal:
Journal of thrombosis and haemostasis
Issue:
Volume 13:Number 7(2015:Jul.)
Page Start:
1217
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Inhibitor development and mortality in non‐severe hemophilia A. (10th June 2015)

Authors:
Eckhardt, C. L.; Loomans, J. I.; van Velzen, A. S.; Peters, M.; Mauser‐Bunschoten, E. P.; Schwaab, R.; Mazzucconi, M. G.; Tagliaferri, A.; Siegmund, B.; Reitter‐Pfoertner, S. E.; van der Bom, J. G.; Fijnvandraat, K.; the INSIGHT Study Group; Fijnvandraat, K.; Peters, M.; Kamphuisen, P. W.; Kamphu...
Journal:
Journal of thrombosis and haemostasis
Issue:
Volume 13:Number 7(2015:Jul.)
Page Start:
1217
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. OP0260 Lower Intestinal Perforations Are More Frequent and Present Untypically in Patients Treated with Tocilizumab Compared To Other Biologic or Conventional Synthetic DMARDS. (15th July 2016)

Authors:
Strangfeld, A.; Richter, A.; Siegmund, B.; Herzer, P.; Rockwitz, K.; Demary, W.; Aringer, M.; Zink, A.; Listing, J.
Journal:
Annals of the rheumatic diseases
Issue:
Volume 75(2016)Supplement 2
Page Start:
156
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Issue 11 (7th October 2016)

Authors:
Stallmach, A.; Langbein, C.; Atreya, R.; Bruns, T.; Dignass, A.; Ende, K.; Hampe, J.; Hartmann, F.; Neurath, M. F.; Maul, J.; Preiss, J. C.; Schmelz, R.; Siegmund, B.; Schulze, H.; Teich, N.; von Arnim, U.; Baumgart, D. C.; Schmidt, C.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 44:Issue 11/12(2016)
Page Start:
1199
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Issue 11 (7th October 2016)

Authors:
Stallmach, A.; Langbein, C.; Atreya, R.; Bruns, T.; Dignass, A.; Ende, K.; Hampe, J.; Hartmann, F.; Neurath, M. F.; Maul, J.; Preiss, J. C.; Schmelz, R.; Siegmund, B.; Schulze, H.; Teich, N.; von Arnim, U.; Baumgart, D. C.; Schmidt, C.
Journal:
Alimentary pharmacology & therapeutics
Issue:
Volume 44:Issue 11/12(2016)
Page Start:
1199
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗